The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following investigational new drug candidate SYNB1353 for the potential treatment of homocystinuria.
Lead Product(s): SYNB2081
Therapeutic Area: Rheumatology Product Name: SYNB2081
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Ginkgo Bioworks
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022